Research programme: CAR T-cell cis-targeted interleukin-21 immunotherapy- Asher Biotherapeutics
Alternative Names: CAR-T cis-targeted IL-21 immunotherapy - Asher Biotherapeutics; Chimeric antigen receptor T-cell cis-targeted interleukin-21 immunotherapyLatest Information Update: 07 Dec 2023
At a glance
- Originator Asher Biotherapeutics
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin 21 replacements; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer